Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Shares Outstanding (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Shares Outstanding for 10 consecutive years, with $64.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Shares Outstanding changed 0.13% to $64.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $64.5 million, a 0.13% change, with the full-year FY2023 number at $64.4 million, up 18.42% from a year prior.
  • Shares Outstanding was $64.5 million for Q1 2025 at Crescent Biopharma, roughly flat from $64.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $64.5 million in Q1 2025 to a low of $51.5 million in Q1 2021.
  • A 5-year average of $58.4 million and a median of $59.3 million in 2022 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 22.79% in 2023, then rose 0.13% in 2025.
  • Crescent Biopharma's Shares Outstanding stood at $52.3 million in 2021, then grew by 3.95% to $54.4 million in 2022, then grew by 18.42% to $64.4 million in 2023, then rose by 0.14% to $64.5 million in 2024, then grew by 0.07% to $64.5 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Shares Outstanding are $64.5 million (Q1 2025), $64.5 million (Q3 2024), and $64.5 million (Q2 2024).